Anti-CD19 CAR T-cell therapy (Shenzhen Institute for Innovation and Translational Medicine)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-CD19 CAR T-cell therapy (Shenzhen Institute for Innovation and Translational Medicine)
Drug Alias Nameyinnuokati-19
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesDongguan People'S HospitalShenzhen Institute For Innovation & Translational Medicine
China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Institute For Innovation & Translational MedicineDongguan People'S Hospital
Inactive CompaniesN/A
Active IndicationsLymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Lymphocytic, Chronic, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A